ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

CMTP Offers Update on NASH Effort, COMET Study April 16, 2018
ICER Publishes Guidance on Improving Development, Use of RWE… April 11, 2018
New ICER Report Reviews Elagolix for Endometriosis May 5, 2018
ICER Releases Report on Plaque Psoriasis Treatments April 28, 2018
ICER Releases Draft Evidence Report on CFTR Modulator… March 16, 2018
ICER Releases Draft Evidence Report on CGRP Inhibitors for… April 12, 2018
ICER Releases Evidence Report on CGRP Inhibitors June 1, 2018